Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

481results about "Mass spectrometric analysis" patented technology

Detection of PFAS compounds in animal tissues

A method of detecting one or more PFAS in a sample of animal tissue, comprising: spraying electrically charged solvent droplets onto the sample of animal tissue so as to generate analyte ions from analyte in the animal tissue; passing the analyte ions into a mass spectrometer; and mass analysing the analyte ions so as to determine if the one or more PFAS is in the animal tissue.
Owner:MICROMASS UK LTD

Detection of vitamins a and e by tandem mass spectrometry

Methods are described for measuring the amount of one or more of vitamin A, α-tocopherol, and the combination of β-tocopherol and γ-tocopherol in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying one or more of vitamin A, α-tocopherol, and the combination of β-tocopherol and γ-tocopherol in a sample.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC

Methods for the detection and treatment of ovarian cancer

A novel 7-marker metabolite panel (7MetP) comprising or consisting of diacetylspermine, diacetylspermidine, N-(3-acetamidopropyl)pyrrolidin-2-one, N-acetylneuraminate, N-acetyl-mannosamine, N-acetyl-lactosamine, and hydroxyisobutyric acid is described.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Methods for determining isomeric amino acid residues of proteins and peptides

The present invention relates to a mass spectrometric method for determining isomeric amino acid residues of a peptide and comprises the steps of: generating a list of peptide candidates using the amino acid lead sequence of the peptide, said lead sequence comprising positions of determined amino acid residues and at least one position with undetermined isomeric amino acid residues; predicting the collision cross section for each peptide candidate; comparing the predicted collision cross section of each peptide candidate with an experimentally determined collision cross section of the peptide and assigning the isomeric amino acid residues of the best matching peptide candidate to the isomeric amino acid residues of the peptide.
Owner:BRUKER DALTONIK GMBH & CO KG

Method for detecting vitamin D in blood by using LDI-MS, and device for same

A method of detecting vitamin D in blood using laser desorption / ionization mass spectrometry (LDI-MS) and an apparatus therefor according to the present invention are not complicated in a measurement, do not require a number of measurement steps, and allow for easy measurement and collection of results in real time with a quick analysis. In addition, precise analysis may be performed even at a lower concentration of a sample, such that sensitivity and precision are excellent, various subtypes of vitamin D may be simultaneously detected, a throughput is high, and structural analysis and quantitative analysis of vitamin D that has undergone a metabolic process in blood may be accurately performed without a matrix interference.
Owner:KOREA RES INST OF STANDARDS & SCI

Biomarkers for metabolic syndrome

The present disclosure relates to biomarkers of metabolic syndrome. In particular, the present disclosure relates to the field of assessing the risk of metabolic syndrome and its complications. It introduces new biomarkers that can be used to predict metabolic syndrome and complications thereof.
Owner:ZORA BIOSCIENCES OY

Mass spectrometry assay for congenital adrenal hyperplasia

Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC

Identification of cervical biomarkers

PendingUS20250334591A1Component separationMicrobiological testing/measurementPregnancyExtravillous trophoblast
Provided herein are methods and kits for identifying a pregnancy-associated risk or condition in a subject. In embodiments, the methods include detecting levels of at least one biomarker in a substantially cell-free cervical fluid sample obtained from the subject. In embodiments, the methods include detecting levels of biomarkers in a cervical fluid sample including extravillous trophoblasts (EVT) obtained from the subject.
Owner:AKNA HEALTH INC

Methods for measuring metabolic dysfunction or risk or presence of an age-associated disease

Provided herein are methods for detecting metabolic dysfunction or risk or presence of an age-associated disease in a subject. Also provided herein are methods for identifying a subject in need of treatment for metabolic dysfunction or risk or presence of an age-associated disease.
Owner:CELLULAR LONGEVITY INC

Diagnostic marker for metabolic syndrome and preclinical stage thereof and application of diagnostic marker

PendingCN119246661AConducive to clinical promotion and applicationHelps with health managementMass spectrometric analysisMaterial analysis by electric/magnetic meansPipequalinePipecolic acid
The invention provides a diagnostic marker for metabolic syndrome and preclinical stage thereof, and the diagnostic marker or a plasma small molecule metabolism biomarker consists of the following substances: pyrimidine, (S)-beta-aminoisobutyric acid, 3-hydroxybutyric acid, L-serine, guanidine acetic acid, 3-hydroxyisovaleric acid, L-homoserine, L-cysteine, piperidine acid, hypotaurine and creatinine. The beverage is prepared from phenylacetic acid, erythritol, picolinic acid, taurine, pyroglutamic acid, lemonic acid, malic acid, tyramine, isonicotinic acid, o-phosphoethanolamine, L-glutamine, salicylic acid and D-glucose. The invention also provides a kit for detecting the plasma small molecule metabolism biomarker composition, the spectrum peak intensity of the obtained plasma small molecule metabolism biomarker is detected, the risk score of whether each subject is MetS or pre-MetS is calculated, and then whether the subject is MetS or pre-MetS is predicted. According to the invention, efficient and rapid diagnosis of the metabolic syndrome and the preclinical stage thereof is realized.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Methods for detecting and treating ovarian cancer

A novel group of 7 marker metabolites (7MetP) is described, which comprises or consists of a diacetyl spermine, a diacetyl spermidine, an N-(3-acetamidopropyl) pyrrolidin-2-one, an N-acetylneuraminic acid ester, an N-acetyl-mannosamine, an N-acetyl-lactosamine, and a hydroxyisobutyric acid.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Mass spectrometry of steroidal compounds in multiplex samples

The invention relates to the quantitative measurement of steroidal compounds by mass spectrometry. In a particular aspect, the invention relates to methods for quantitative measurement of steroidal compounds from multiple samples by mass spectrometry.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC

Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved hmwk

PendingUS20250172567A1Component separationMass spectrometric analysisHigh-molecular-weight kininogenOrganic chemistry
Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and / or full-length HMWK.
Owner:TAKEDA PHARMA CO LTD

Methods of detecting and treating colorectal pancreatic ductal adenocarcinoma

To provide methods and related kits for detecting early stage pancreatic ductal adenocarcinoma, and methods of treating a patient susceptible, or suspected of being susceptible, to pancreatic ductal adenocarcinoma.SOLUTION: A method of determining susceptibility of a patient to pancreatic ductal adenocarcinoma is provided, the method comprising obtaining a biological sample from the patient, measuring the level of CA19-9 antigen in the biological sample, measuring the level of TIMP1 antigen in the biological sample, and measuring the level of LRG1 antigen in the biological sample, where the amounts of CA19-9 antigen, TIMP1 antigen, and LRG1 antigen classifies the patient as being susceptible to pancreatic ductal adenocarcinoma or not susceptible to pancreatic ductal adenocarcinoma.SELECTED DRAWING: None
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Mass spectrometry apparatus, method for evaluating and calibrating the same, method for analyzing sample, and reagent

The present invention provides a quality analysis device, an evaluation and calibration method thereof, an analysis method, and a reagent. The evaluation method of the quality analysis device includes: performing quality analysis on an ester of phthalic acid using the quality analysis device to detect a plurality of ions generated by dissociation of the ester of phthalic acid; and obtaining information on whether the quality analysis device is in a state suitable for analysis based on the intensity ratio of the plurality of detected ions.
Owner:SHIMADZU SEISAKUSHO LTD

Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury

The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and / or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and / or TBI risk stratification tool as part of assessing a subject's TBI status.
Owner:ABBOTT LAB INC +1

Methods for diagnosing, detecting, or assessing cancer using isotope analysis

By adapting isotopic fingerprinting to the human body, experimental data revealed a specific chemical fingerprint of cancer, such as prostate cancer, "fossilized" in samples such as a patient's hair or nails. To interpret the isotopic chemical data of the samples, a predictive model was developed using machine learning algorithms and several dimensions to enable population differentiation. In several aspects, this provides a non-invasive method for cancer diagnosis, detection, or assessment developed by identifying the chemical fingerprint of cancer. TIFF2026509162000028.tif53159
Owner:LUC INNOVATIONS AB +1

Methods for detecting estrone by mass spectrometry

Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC

Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring

To provide methods of identifying and using glycopeptides as biomarkers for diagnosis and treatment monitoring.SOLUTION: Provided herein are methods of identifying new biomarkers for various diseases using proteomics, peptidomics, metabolics, proteoglycomics, glycomics, mass spectrometry and machine learning. The present disclosure also provides glycopeptides as biomarkers for various diseases such as cancer and autoimmune diseases.SELECTED DRAWING: Figure 1
Owner:VENN BIOSCIENCES CORP

Bacteria engineered to reduce hyperphenylalaninemia

PendingJP2026086510ABacteriaHydrolasesPhenylalanine transportEngineered genetic
This invention provides compositions and treatment methods for reducing hyperphenylalaninemia. [Solution] A genetically modified bacterium is provided, comprising: a) one or more genes encoding phenylalanine ammonia lyase (PAL), which are operably linked to a promoter that is not naturally associated with the PAL gene and can be directly or indirectly induced; b) one or more genes encoding a phenylalanine transporter, which are not naturally associated with the phenylalanine transporter gene and can be operably linked to a promoter that is directly or indirectly induceable; and c) one or more genes encoding mutant fumarate and nitrate reductase (FNR), which are not naturally associated with the FNR gene and can be operably linked to a promoter that is directly or indirectly induceable.
Owner:SYNLOGIC OPERATING CO INC

IROA Metabolomics Workflow for Improved Accuracy, Identification and Quantitation

An IROA Matrix of metabolite compounds is disclosed. Each of whose compounds has a molecular weight of 2000 AMU or less, and is present as first and second isotopomers that are equally present at two predetermined isotopomeric balances, and contain 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. A reagent pair for transforming a natural abundance mass spectral analysis metabolite sample into an IROA sample is also disclosed and comprises two reactively identical reagents that constitute first and second isotopomers containing 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. Each of the reagent pair contains the same reactive group that reacts with and bonds to a functional group of one or more compounds present in a composition of biologically-produced metabolite compounds. Methods of making and using the above and related materials are also disclosed.
Owner:IROA TECHNOLOGIES LLC

Method for preparing a sample solution containing neurogranin-related peptides and method for analyzing neurogranin-related peptides.

Provided are: a method which is for analyzing a neurogranin-related peptide and can suppress deviations in analysis results; and a method for preparing a biological sample containing the neurogranin-related peptide used for same. A method for preparing a sample solution containing a neurogranin-related peptide involves mixing a biological sample containing the neurogranin-related peptide with an organic solvent having a relative polarity of 0.200 to 0.700 to prepare a sample solution containing the organic solvent having a final concentration of at least 5.0 (v / v)%.
Owner:SHIMADZU SEISAKUSHO LTD

Application of metabolic marker in preparation of product for diagnosing abdominal aortic aneurysm

The invention belongs to the technical field of biological medicine, and particularly relates to application of a metabolic marker in preparation of a product for diagnosing abdominal aortic aneurysm. The metabolic marker comprises one or more than two of 5-delta-hydroxybutyl hydantoin, I-alpha-amino acid, PGF2 alpha, D-pyroglutamic acid, nicotine glucuronide, cysteine glutathione disulfide or Trp-P-1. Experiments prove that the metabolic marker has the advantages that the metabolic marker can be applied to the field of biomarkers, and the metabolic marker can be applied to the field of biomarkers; the seven metabolites are independently or jointly used as metabolic markers for diagnosing the abdominal aortic aneurysm and have good specificity and sensitivity.
Owner:BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV +1

Diagnosis of metabolic changes of the liver by way of metabolic analysis of erythrocytes by mass spectrometry

The invention relates to a method for analyzing a biological sample for changes in signatures of key metabolites in a hepatic disease, comprising (a) isolating erythrocytes from the biological sample, (b) identifying and optionally quantifying lipids from the erythrocytes as the key metabolites for a hepatic and infectious disease, including the lipids PC (28:0), PC (30:0), PC (30:1), PC (32:0), PC (32:1), PC (34:0), PC (34:1), PC (34:2), PC (36:0), PC (36:1), PC (36:2), PC (36:3), PC (36:4), PC (38:0), PC (38:1), PC (38:2), PC (38:3) and PC (38:4); SM (17:0), SM (12:0), SM (14:0), SM (16:0), SM (18:0), SM (18:1), SM (20:0), SM (22:0), SM (24:0), SM (24:1), SM (26:0) and SM (26:1); LPE (16:0), LPE (16:1), LPE (18:0), LPE (18:1), LPE (18:2) and LPE (20:4); Cer (15:0), Cer (12:0), Cer (14:0), Cer (16:0), Cer (18:0), Cer (18:1), Cer (20:0), Cer (22:0), Cer (24:0) and Cer (24:1); LPC (16:0), LPC (16:1), LPC (17:0), LPC (18:0), LPC (18:1), LPC (18:2), LPC (20:0), LPC (20:1), LPC (20:3) and LPC (20:4), and LPE (16:0), LPE (16:1), LPE (17:1), LPE (18:0), LPE (18:1), LPE (18:2) and LPE (20:4); (c) carrying out principal component analysis of the samples and clustering according to subgroups; (d) identifying key metabolites by means of XGBoost algorithm; (e) detecting the changes in the key signatures of the key metabolites of the hepatic disease identified in step (d), and (f) diagnosing a hepatic disease. The invention further relates to the use of the results of this method in personalized medicine.
Owner:UNIVSKLINIKUM JENA

Quality control standard solution used in peptide assay, and quality control of peptide assay

A quality control standard for peptide (including protein) measurement, and a quality control for peptide (including proteins) measurement are provided. A QC standard sample for measurement of a target peptide, the QC standard sample comprising: a blood sample comprising a peptide, and a peptide labeled with a stable isotope that is spiked into said blood sample. The target peptide to be measured includes, for example, at least one selected from the group consisting of Aβ1-42 (SEQ ID NO.: 9), Aβ1-38 (SEQ ID NO.: 11), Aβ1-40 (SEQ ID NO.: 7), and APP669-711 (SEQ ID NO.: 10). The peptide labeled with a stable isotope that is spiked into the blood sample includes, for example, at least one selected from the group consisting of SIL-Aβ1-42, SIL-Aβ1-38, SIL-Aβ1-40, and SIL-APP669-711.
Owner:SHIMADZU CORP